Own immune cells delivered to liver to fight melanoma
NCT ID NCT04812470
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested whether it is safe and feasible to give patients their own immune cells (called tumor infiltrating lymphocytes, or TIL) directly into the liver artery. Eight adults with melanoma that had spread to the liver received the TIL infusion along with chemotherapy and an immune booster. The main goal was to check for side effects and see if the approach is practical.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
autologous tumor infiltrating lymphocytes (TIL) plus melphalan and interleukin-2
What this could lead to
If it works, this could point toward a new way to treat melanoma that has spread to the liver using the patient's own immune cells.
What could go wrong
This is a very early phase 1 trial with only 8 people, so it is too small to prove effectiveness. The treatment involves strong chemotherapy and immune stimulation, which can cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Oncology, Sahlgrenska University Hospital
Gothenburg, Sweden